Enlitic Curie

Who is Enlitic?

Enlitic, Inc. was founded in 2014 by Jeremy Howard, and Kevin Lyman is also named as a founder, according to the Crunchbase and Tracxn profiles. Those profiles put total funding at about $55 million to $57 million over five to six rounds, and the last venture round was a $25 million Series B in November 2019. Named investors include Amplify Partners, Marubeni, Capitol Health and Regal Funds Management.

The same profiles report that Enlitic bought Laitek for $5 million, which added 55 employees and $6.8 million in revenue. Crunchbase also lists Enlitic on the Australian Securities Exchange under the ticker ENL. It places the company in Loveland, Colorado, while CB Insights and Built In list Fort Collins.

What does the platform do?

Curie standardizes DICOM files and their metadata for imaging departments. The applications named in the fda.report entry are Standardize, Curie|ENDEX and Ensight.

What were the 2022 approvals?

Applied Radiology headlined its report "Enlitic Curie platform nets FDA clearance, CE marking" and AuntMinnie reported that the software was approved for commercialization in the US and EU. Both are dated May 26, 2022, and neither gives an integration list. The CE marking falls under the EU Medical Device Regulation.

The FDA's 510(k) database shows no Enlitic applicant, so a clearance may be filed under another name or product code. The fda.report site lists an entry titled "Enlitic Curie" dated February 28, 2022, with Standardize, Curie|ENDEX and Ensight beside it.

Is there a price for Curie?

Enlitic's price is not public, and no tier, billing period or trial is listed.

The verdict

Curie fits an imaging department or imaging AI deployment that needs standardized DICOM data, and the May 2022 announcements are the regulatory record behind it. A US buyer who must put a 510(k) number in a procurement file has none to cite from the announcements or the FDA database. Enlitic's last venture round was the $25 million Series B in November 2019.